Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Can-Fite BioPharma ( (CANF) ) is now available.
On October 3, 2025, Can-Fite BioPharma Ltd. announced it will hold a Special General Meeting of Shareholders on November 3, 2025, at its offices in Ramat Gan, Israel. The meeting will address two key proposals: increasing the company’s authorized share capital by 22 billion shares and approving a reverse stock split at a ratio of 1:3000. These actions are intended to enhance the company’s capital structure and potentially improve its market position. Shareholders and American Depositary Shareholders are invited to vote on these proposals, which are recommended by the company’s Board of Directors.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score reflects significant financial challenges and bearish technical indicators. The company’s persistent financial losses and reliance on external financing are major concerns, compounded by negative technical signals. The absence of profitability metrics further underscores the risks associated with this stock.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company based in Israel, focusing on the development of small molecule drugs for the treatment of autoimmune inflammatory diseases, cancer, and liver diseases. The company is engaged in clinical trials and research to advance its therapeutic products, aiming to address significant unmet medical needs in these areas.
Average Trading Volume: 204,383
Technical Sentiment Signal: Sell
Current Market Cap: $15.43M
Learn more about CANF stock on TipRanks’ Stock Analysis page.